LEEDS, England, February 12 /PRNewswire/ --
- Teva UK Limited has Launched a New Website.
The new website, which is at http://www.tevauk.com, has been fully updated with a fresh new approach and contemporary design. Teva believes the new site will provide comprehensive information about the company to its customers, partners and employees alike.
John Beighton, Managing Director of Teva UK Limited, said: "The new website is a major step forward for Teva and is part of our ongoing drive to provide the best possible communication with our customers and other key stakeholders. We feel that the site showcases the strength of our business as a market leader. The graphic design is designed to help to communicate our core business values and the site is easy to navigate."
The new site includes:
- Clear design and navigation for users
- Detailed information about the company business and products
- Adverse drug reaction reporting facility
- Up-to-date news section, including fully searchable archive
- Interactive poll enabling visitors to vote on current "hot topics" in healthcare
- For the first time, the Teva UK Limited website also has a careers section, giving people the opportunity to become a part of the company's future
The company hopes the website will be developed over time to include a comprehensive learning resource for its customers.
The launch is also being supported by a comprehensive advertising campaign.
Notes to editors:
Teva UK Limited is one of the UK's leading pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. With over 500 product lines, it has the widest range of any UK generic pharmaceutical company and has a number of innovative respiratory products including the Qvar(R) (beclometasone dipropionate) CFC-free inhaler.
Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: Teva`s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which Teva may obtain U.S. market exclusivity for certain of its new generic products and regulatory changes that may prevent Teva from utilizing exclusivity periods, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the impact of consolidation of our distributors and customers, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra(R), Neurontin(R), Lotrel(R), and Famvir(R), the effects of competition on our innovative products, especially Copaxone(R) sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, environmental risks, fluctuations in currency, exchange and interest rates, and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Media enquiries: Philippa Ward, Communications & PR Officer, +44(0)113-201-3972.